FDA Drug Recalls

Recalls / Class III

Class IIID-1335-2022

Product

Zynrelef (bupivacaine and meloxicam), 400 mg bupivacaine and 12 mg meloxicam single dose application, packaged in a kit, Rx only, Manufactured for Heron Therapeutics, Inc., San Diego, CA, NDC 47426-301-02

Brand name
Zynrelef
Generic name
Bupivacaine And Meloxicam
Active ingredients
Bupivacaine, Meloxicam
Route
Infiltration
NDCs
47426-301, 47426-302, 47426-303, 47426-304, 47426-501, 47426-502, 47426-503, 47426-504
FDA application
NDA211988
Affected lot / code info
Lot #: 01126739, Exp 7/31/2023

Why it was recalled

Defective Delivery System: An incorrect 10 mL (12 mL) Luer (slip) syringe packaged in one lot of Zynrelef 400 mg/12 mg kit

Recalling firm

Firm
HERON THERAPEUTICS, INC.
Manufacturer
Heron Therapeutics, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
4242 Campus Point Ct Ste 200, San Diego, California 92121-1513

Distribution

Quantity
1790 kits
Distribution pattern
U.S.A. Nationwide

Timeline

Recall initiated
2022-08-02
FDA classified
2022-08-12
Posted by FDA
2022-08-24
Terminated
2023-09-29
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1335-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class III recall: Zynrelef · FDA Drug Recalls